Home › Upcoming votes › TScan Therapeutics, Inc.
The deadline as the proxy statement states it: “Votes submitted through the Internet must be received by 11:59 p.m. Eastern Time, on November 19, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGAR
Ballot read from the proxy statement and checked. As listed in TScan Therapeutics, Inc.’s proxy statement, with the board’s recommendation on each item.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | Approval of an amendment to the Certificate of Incorporation to effect the Reverse Stock Split | Board | For | — |
| 2 | THE ADJOURNMENT PROPOSAL Adjournment |
Board | For | — |
From TScan Therapeutics, Inc.’s Form 8-K, filed July 2, 2025, for the meeting held June 30, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Stephen Biggar, M.D., Ph.D. | 99% | — |
| Elect Director: Gavin MacBeath, Ph.D. | 99.0% | — |
| Elect Director: Garry Nicholson | 81% | — |
| 2. Ratification of Appointment of Independent Registered Public Accounting Firm | 99.8% | Approved |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.